Keywords: EULAR, Novartis, Johnson & Johnson, Bristol-Myers Sqibb, Ilaris, Canakinumab, Stelara, Simponi, Orencia

More news at EULAR from Novartis, J&S and B-MS

Article | 07 June 2012

Print This

Highlights presented at the annual congress of the European League Against Rheumatism (EULAR 2012), in Berlin, Germany, include new data from ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in